Navigation Links
Anti Cancer Drug from Blue Green Algae

Anti cancer drugs have been created from blue green algae by scientists with the knowledge of synthetic chemistry techniques//. Besides this, the information on properties and actions of enzymes is also taken into consideration.

This accomplishment is expected to make it possible to produce enough of the promising drugs for use in clinical trials.

In a study featured on the cover of the January issue of the journal ACS Chemical Biology, a scientific team lead by University of Michigan Life Sciences Institute Research Professor David H. Sherman and researcher Zachary Q. Beck found the trick to turning the green gunk into gold—cancer fighting gold.

"It was simply too difficult to use the native blue-green algae for high-level production using traditional fermentation approaches," said Sherman. But the compound, called cryptophycin 1, held so much promise as an anti-cancer drug that organic chemists got busy trying to find ways to make a synthetic form of the compound in large enough quantities for clinical trials.

Developing an efficient synthetic route to natural product compounds and their analogs is often an essential step in drug development. With drugs such as penicillin and tetracycline, it can easily be done, but cryptophycins present more of a challenge. Sherman's team realized that with all cryptophycins, the most difficult step came very late in the synthesis, at the point at which a key part called an epoxide—a highly strained, three-membered ring oxygen-containing group, crucial for the drug's anti-cancer activity—becomes attached to the molecule.

The epoxide group can be attached in two configurations, designated as alpha and beta. Scientists have known for several years that the beta configuration was absolutely required for the anti-cancer properties of the drug, but were unable to devise efficient synthetic strategies that favored that configuration.

Sherman's team accomplished this by isolati ng the entire set of biosynthetic genes and key enzymes and developing a new, efficient method to manufacture the broad class of cryptophycin natural products, including important analogs with clinical potential. This included characterization of an enzyme, cytochrome P450, that always introduces the epoxide in the desired beta configuration.

Sherman, who is also the John G. Searle Professor of Medicinal Chemistry in the College of Pharmacy, believes that this approach will allow effective new cryptophycin analogs with low levels of side effects to be created for clinical trials.

"This issue represented an exciting target that offered not only an interesting scientific problem, but the potential to do something of practical importance in creating a promising anti-cancer drug," he said.

Source-Eurekalert
JT
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... of a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided ... nation’s largest healthcare systems recently invested $51 million to purchase and renovate the ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... secure messaging services to the largest network of hospitals, health information exchanges, ... National Coordinator for Health Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, ... or not filling a prescription because they could not afford to pay for ... medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... and VANCOUVER, British Columbia ... OGXI ) today announced its year end ... In January 2017, OncoGenex, and Achieve Life Science, ... they have entered into a definitive merger agreement under ... Upon completion of the proposed merger, Achieve,s stockholders are ...
Breaking Medicine Technology: